Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 680 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Vaccine 2 Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Increasing Optimal Use of HPV Vaccination in Primary Care

NCT04180462
View directory record Official record
Conditions
Human Papillomavirus Vaccines
Interventions
Practice Facilitation, Education, Audit and Feedback, Communication Strategy
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 18, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

NCT00912496
View directory record Official record
Conditions
Influenza
Interventions
MF-59, A/Anhui/05, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
637 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
10
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 18, 2026, 4:10 AM EDT
Completed Phase 1 Interventional

Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects

NCT02431312
View directory record Official record
Conditions
Hepatitis B
Interventions
INO-1800, INO-9112, Nucleos(t)ide Analogue Treatment
Biological · Drug
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
San Diego, California • Miami, Florida • Manhasset, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 18, 2026, 4:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Immunization Delivery in Obstetrics and Gynecology Settings

NCT01565135
View directory record Official record
Conditions
Immunization Status Among Obstetrics and Gynecology Patients
Interventions
Multimodal Vaccine Program
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
15 Years and older · Female only
Enrollment
97,087 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 18, 2026, 4:10 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

NCT04060277
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions
Letermovir, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Placebo Administration
Drug · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 18, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels

NCT01770743
View directory record Official record
Conditions
Anthrax
Interventions
AV7909, BioThrax
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 50 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
4
States / cities
Miami, Florida • Mt. Pleasant, South Carolina • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 18, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults

NCT03341754
View directory record Official record
Conditions
Malaria
Interventions
D/ChAd63-CA, D/ChAd63-CAT, Infectivity Control (IC) Group
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Bethesda, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 18, 2026, 4:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

NCT01144637
View directory record Official record
Conditions
Smallpox
Interventions
IMVAMUNE®, Placebo
Biological · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 40 Years
Enrollment
4,005 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
34
States / cities
Birmingham, Alabama • Anaheim, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 18, 2026, 4:10 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

NCT05216510
View directory record Official record
Conditions
Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
Interventions
TNX-2110, TNX-2120, TNX-2130, CANDIN, Diluent
Biological
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 18, 2026, 4:10 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

BPL-1357 Against H1N1 Influenza Virus Challenge

NCT07215858
View directory record Official record
Conditions
Influenza, Human
Interventions
BPL-1357 IM, BPL-1357 IN, Placebo IM, Placebo IN
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Bethesda, Maryland • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 4:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

NCT06316297
View directory record Official record
Conditions
Acne
Interventions
Acne mRNA vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
79
States / cities
Scottsdale, Arizona • Cerritos, California • Encino, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 18, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

NCT00297817
View directory record Official record
Conditions
Meningococcal Disease
Interventions
serogroup B meningococcal vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
11 Years to 18 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
8
States / cities
Encinitas, California • Atlanta, Georgia • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 18, 2026, 4:10 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath

NCT04794218
View directory record Official record
Conditions
Lassa Fever, Lassa Virus Infection
Interventions
rVSV∆G-LASV-GPC, Placebo/Diluent
Drug · Other
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 51 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Honolulu, Hawaii • Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 18, 2026, 4:10 AM EDT
Active, not recruiting Phase 2 Interventional

Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer

NCT05638698
View directory record Official record
Conditions
Pancreas Cancer
Interventions
TG01 Vaccine, QS-21, Balstilimab
Biological · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Fairway, Kansas • Overland Park, Kansas • Westwood, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 18, 2026, 4:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01579916
View directory record Official record
Conditions
Influenza
Interventions
Trivalent Influenza Virus Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 18, 2026, 4:10 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Influenza Vaccine Post Allogeneic Transplant

NCT01215981
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant, Hematologic Malignancy
Interventions
Influenza vaccine
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
6 Months and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 18, 2026, 4:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

NCT03342898
View directory record Official record
Conditions
Dengue
Interventions
YF-17D, TDV, Placebo
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
11
States / cities
Mobile, Alabama • Pomona, California • Meridian, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 18, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults

NCT04232280
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
mRNA-1647, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
9
States / cities
Sacramento, California • Peoria, Illinois • Lenexa, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 18, 2026, 4:10 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults

NCT06803342
View directory record Official record
Conditions
Ebola Sudan Virus Disease
Interventions
cAd3-Sudan Vaccine, Placebo
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Melbourne, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 18, 2026, 4:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Post Marking Study to Evaluate the Safety of FluMist in Children

NCT00569894
View directory record Official record
Conditions
Healthy
Interventions
FLuMist, TIV (Injection), Unvaccinated Control
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
24 Months to 59 Months
Enrollment
29,296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 18, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Norwalk Vaccine Study

NCT00806962
View directory record Official record
Conditions
Norovirus
Interventions
Adjuvant/Excipients, placebo, Norwalk VLP Vaccine
Drug · Device · Biological
Lead sponsor
LigoCyte Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 18, 2026, 4:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

NCT04228783
View directory record Official record
Conditions
Ebola
Interventions
Ad26.ZEBOV, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
974 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
7
States / cities
Mobile, Alabama • Tempe, Arizona • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 18, 2026, 4:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults

NCT04816669
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b2
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
629 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
21
States / cities
Anaheim, California • Walnut Creek, California • Hialeah, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 18, 2026, 4:10 AM EDT
Terminated Phase 2 Interventional Results available

A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

NCT03547999
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
mFOLFOX6, MVA-BN-CV301, FPV-CV301, Nivolumab
Drug · Biological
Lead sponsor
Patrick Boland
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Duarte, California • Miami, Florida • Westwood, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 18, 2026, 4:10 AM EDT